Telix agrees to buy Germany’s ITM, and the market flinches
The Melbourne radiopharmaceutical company’s deal is worth up to US$2.35 billion; its shares fell almost 12%.

Telix will pay US$1.65 billion (about A$2.3 billion) upfront for Munich-based ITM Isotope Technologies, including US$1.25 billion in Telix shares at US$11.84. Up to US$700 million more depends on FDA approval and sales milestones, taking the possible total to about A$3.3 billion.
ITM is Germany’s leading supplier of therapeutic radioisotopes, in particular lutetium-177 for cancer treatment.
Telix shares fell 11.7% to $15.76 on 21 September. Afterwards Telix holders will own about 76% of the company. Shareholders vote in November.
Read Next
More business
ASX claws back to 8,810 as oil above US$114 keeps rate fears alive
The benchmark closed higher on Monday after an early slide, with Brent crude near six-month highs and a takeover wave reshaping the index.

Zip sheds nearly 30pc after a US fraud ring hits growth
The buy-now-pay-later lender said coordinated fraudsters opened accounts with legitimate credentials, costing A$10.1 million.

NEXTDC shares fall 42% after power delays cut guidance
Community opposition to grid works near its Melbourne M3 data centre led the company to remove $140 million of contracts from its forecasts.

